215 related articles for article (PubMed ID: 9816165)
1. Thymidylate synthase inhibitors.
Touroutoglou N; Pazdur R
Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
[TBL] [Abstract][Full Text] [Related]
2. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
3. Future challenges in the clinical development of thymidylate synthase inhibitor compounds.
Brandt DS; Chu E
Oncol Res; 1997; 9(8):403-10. PubMed ID: 9436193
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.
Chu E; Callender MA; Farrell MP; Schmitz JC
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S80-9. PubMed ID: 12819937
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase inhibitors.
Danenberg PV; Malli H; Swenson S
Semin Oncol; 1999 Dec; 26(6):621-31. PubMed ID: 10606255
[TBL] [Abstract][Full Text] [Related]
6. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
7. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
Hanlon MH; Ferone R
Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
[TBL] [Abstract][Full Text] [Related]
8. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
[TBL] [Abstract][Full Text] [Related]
9. Folate-based thymidylate synthase inhibitors in cancer chemotherapy.
Takemura Y; Jackman AL
Anticancer Drugs; 1997 Jan; 8(1):3-16. PubMed ID: 9147608
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation.
Jackman AL; Kimbell R; Brown M; Brunton L; Bisset GM; Bavetsias V; Marsham P; Hughes LR; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):573-89. PubMed ID: 7495480
[TBL] [Abstract][Full Text] [Related]
12. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
[TBL] [Abstract][Full Text] [Related]
13. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
15. Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.
Harrap KR
Cancer Res; 1995 Jul; 55(13):2761-8. PubMed ID: 7796401
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
[TBL] [Abstract][Full Text] [Related]
17. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery.
Jackman AL; Boyle FT; Harrap KR
Invest New Drugs; 1996; 14(3):305-16. PubMed ID: 8958186
[TBL] [Abstract][Full Text] [Related]
18. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
[TBL] [Abstract][Full Text] [Related]
19. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
[TBL] [Abstract][Full Text] [Related]
20. Folate-based inhibitors of thymidylate synthase: synthesis and antitumor activity of gamma-linked sterically hindered dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Bavetsias V; Jackman AL; Marriott JH; Kimbell R; Gibson W; Boyle FT; Bisset GM
J Med Chem; 1997 May; 40(10):1495-510. PubMed ID: 9154971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]